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Introduction
Anatomic and pathologic staging remain the most accurate predictors
of clinical outcomes in patients with colorectal cancer, enabling physicians
to evaluate the benefit of adjuvant chemotherapy for individual patients.
However, supplementing standard clinical and pathologic staging using
molecular markers would allow more precise identification of those pa-
tients with the highest, or lowest, risk of relapse following colorectal cancer
surgery. One of the most promising molecular markers that have been in-
vestigated in relation to colorectal cancer is the presence of tumor mi-
crosatellite instability. In a meta-analysis, colorectal cancers with mi-
crosatellite instability had a significantly better prognosis compared to
those with intact mismatch repair, and these tumors may be resistant to
treatment with 5-fluorouracil [1].
Apoptosis is an essential physiological process in maintaining normal
tissue homeostasis, cellular differentiation and development [2,3]. It is
well known that defects in apoptosis facilitate the accumulation of somatic
mutations which thereby contribute to tumor initiation, progression, and
metastasis [4-6]. Caspases (CASPs), a family of cystein-dependent as-
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Purpose
This study analyzed potentially functional polymorphisms in CASPASE (CASP) genes and their
impact on the prognosis for Korean colorectal cancer patients. 
Materials and Methods
A total of 397 consecutive patients with curatively resected colorectal adenocarcinoma were 
enrolled in this study. Genomic DNA from these patients was extracted from fresh colorectal 
tissue, and the 10 polymorphisms in the CASP3, CASP6, CASP7, CASP8, CASP9, and CASP10
genes were determined using a reverse transcription polymerase chain reaction genotyping
assay. 
Results
The median patient age was 63 years, and 218 (54.9%) patients had colon cancer, while 179 (45.1%)
patients had rectal cancer. Univariate and multivariate survival analysis including pathologic
stage, patient age, differentiation, and carcinoembryonic antigen level demonstrated that these 
polymorphisms were not associated with either disease-free or overall survival. 
Conclusion
None of the 10 polymorphisms in the CASPgenes investigated in this study was found to be an
independent prognostic marker for Korean patients with curatively resected colorectal cancer.
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partate-specific proteases, play a crucial role in the regulation and execu-
tion of apoptosis [7-9], and based on their proapoptotic function, they can
be separated into initiator and effector CASPs. Initiator CASPs (CASP8,
CASP9, and CASP10) transmit apoptotic signals, and activation of ef-
fector CASPs (CASP3, CASP6, and CASP7) function to execute the final
cell death program [7-10].
Many polymorphisms identified in the CASPgenes are putatively func-
tional, and clinical studies have demonstrated that these polymorphisms
are involved in the development of solid tumors such as colorectal [11],
lung [12,13], breast [14], and malignant melanoma [15]. For example,
CASP9 gene  polymorphisms  and  their  haplotypes,  -1263A＞G
(rs4645978) and -712C＞T (rs4645981), have been reported to both affect
CASP9 expression and modulate lung cancer risk [12]. The V410I
(rs13010627G＞A) and I522L (rs13006529A＞T) polymorphisms of
the CASP10gene have been reported to be associated with the risk of de-
veloping cutaneous melanoma and familial breast cancer [15,16]. Fur-
thermore, the CASP7rs2227310 and CASP9rs4645981 polymorphisms
have been identified as independent prognostic markers for patients with
surgically resected, non-small cell lung cancer (NSCLC) [17]. Given these
results, CASPgene polymorphisms appear to play a role in the carcino-
genesis or prognosis of solid tumors. 
Nonetheless, relatively few studies have investigated the single nu-
cleotide polymorphisms (SNPs) in the CASPgenes and their relationship
to the clinical outcomes of colorectal cancer. Accordingly, this study an-
alyzed 10 CASPgene polymorphisms and evaluated their impact on the
prognosis of colorectal cancer patients.
M ater ials  and  M eth od s
1. Study population
All the tissues investigated in this study were obtained from 397 con-
secutive, ethnic Korean, colorectal cancer patients who had undergone a
curative resection between January 2003 and August 2006, at Kyungpook
National University Hospital (Daegu, Korea). Written informed consent
for gene expression analyses was received from all participating patients
prior to surgery, and the study was approved by the Kyungpook National
University Hospital Institutional Research Board. The diagnosis and stag-
ing of the colorectal cancer data was performed according to World Health
Organization (WHO) classifications [18] and the tumor, node, and metas-
tasis (TNM) classifications set by the American Joint Committee on Can-
cer (AJCC) [19].
2. Selection of CASPgene polymorphisms
Due to the enormous number of SNPs in the human genome, an ap-
propriate strategy for efficient selection of those SNPs most likely to con-
tribute phenotypic effects was our first challenge. Thus, a prioritization
scheme was created using public databases providing diverse information
on potential phenotypic risks associated with specific SNPs. First, candi-
date SNPs from CASPgenes were collected from web-based databases
which included information on the biologic pathways and potential bio-
logic effects of these polymorphisms. Next, based on the allele frequencies
recorded for East Asian populations obtained from FASTSNP, those SNPs
with frequencies less than 0.1 were excluded. The remaining CASPgene
SNPs were then scored according to particular phenotypic risks, and then,
based on the algorithm suggested in a previous report [20], they were or-
dered according to the sum of their risk scores. Among the 13 polymor-
phisms in the CASP3, CASP6, CASP7, CASP8, CASP9, and CASP10
genes that have been reported to be potentially functional or otherwise as-
sociated with cancer risk [11-16], ten polymorphisms (CASP3rs2705897;
CASP6rs1042891, rs2301717; CASP7rs2227310, rs11593766; CASP8
rs3769818,  rs3834129;  CASP9 rs1052571,  rs4645978;  CASP10
rs13006529)  were  examined.  CASP8 rs1045485  and  CASP10
rs13010627 were excluded as they are rare or nonexistent in Asian pop-
ulations [11,21]. 
3. Genotyping CASPgene polymorphisms
Genomic DNA was extracted from fresh colorectal mucosal tissue at
the time of surgery using a Wizard genomic DNA purification kit
(Promega, Madison, WI). The 10 selected CASP gene polymorphisms
were then determined using a reverse transcription polymerase chain re-
action (PCR) genotyping assay. For quality control, the genotyping analy-
sis was performed blind as regards the subjects. 
The selected, PCR-amplified DNA samples (n=2, for each genotype)
were also examined by DNA sequencing to confirm the genotyping re-
sults.
4. Statistical analysis
The genotypes for each SNP were analyzed as a categorical variable
for three-groups (reference model), and also grouped according to a dom-
inant and recessive model. The survival estimates were calculated using
the Kaplan-Meier method. As related to the appearance of SNPs of the
CASP genes, the differences in patient overall survival (OS) or disease-
free survival (DFS), were compared using log-rank tests. Cox’s propor-
tional hazard regression model was used for the multivariate survival
analyses, whereby the analyses were adjusted for potential prognostic fac-
tors including age (median age, 63 years;≤63 years vs.＞63 years), dif-
ferentiation (well to poor differentiation), preoperative carcinoembryonic
antigen (CEA) level (normal vs. elevated), and pathologic stage (0 to IV).
The hazard ratio and 95% confidence interval were also estimated. A cut-
off p-value of 0.05 was adopted for all statistical analyses. The statistical
data were obtained using an SPSS ver. 11.5 (SPSS Inc., Chicago, IL) or
SAS Genetic software (SAS Institute, Cary, NC). 
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Results
1. Patient characteristics and survival analysis
The median age of the patients was 63 years (range, 21 to 85 years),
and 217 (54.7%) of the total patients were male. Of the total patients, 218
(54.9%) were diagnosed with colon cancer and the remaining with rectal
cancer. Laparoscopic surgery was performed on 271 (68.3%) patients,
while the others received an open colorectal resection. The pathologic
stages after the surgical resection were as follows: stage 0/I (n=86, 21.7%),
stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20,
5.0%). Among the 291 patients with stage II or III disease, 275 (94.5%)
received  adjuvant  chemotherapy  using  either  6  cycles  of  5-
fluorouracil/leucovorin ± radiotherapy (n=133), 12 cycles of oxaloplatin,
leucovorin, and fluorouracil (FOLFOX-4) (n=12), 8 cycles of capecitabine
(n=20), or doxifluridine during a treatment period of one year (n=110)
(Table 1). 
At the time of the last analysis, 80 patients had experienced disease re-
lapse and 37 had died as a result of colorectal cancer disease progression.
However, the deaths of 2 patients were unrelated to colorectal cancer. At
the median follow-up duration of 34.8 months (range, 1.1 to 65.7 months),
the estimated 5-year OS and DFS for all the patients was 89.3±1.6% and
72.3±4.3%, respectively. Survival results differed according to the patho-
logic stage (p＜0.001).
2. Association of genotype frequency with clinicopathologic features
and survival
The 10 CASP gene SNPs were successfully amplified in more than
95% of patients. The frequencies of occurrence for each genotype also
conformed to the Hardy-Weinberg equilibrium (p＞0.05). There were no
sexual differences observed in relation to any genotype and allele. No cor-
Characteristics    
No. (%)
(n=397)
Median age (range, yr) 63 (21-85)
Gender 
Male 217 (54.7)
Female 180 (45.3)
Primary site
Colon 218 (54.9)
Rectum 179 (45.1)
Hereditary cancer
Familial adenomatous polyposis 7 (1.8)
Hereditary nonpolyposis colorectal cancer 6 (1.5)
Histological differentiation
Well 83 (20.9)
Moderate 300 (75.6)
Poor or signet ring 14 (3.5)
CEA, elevated  78 (19.6)
Surgery
Open 126 (31.7)
Laparoscopy  271 (68.3)
Pathologic stage
0/I 86 (21.7)
II 146 (36.8)
III 145 (36.5)
IV 20 (5.0)
Adjuvant chemotherapy (n=275)
5-fluorouracil/leucovorin±radiotherapy 133 (48.4)
FOLFOX-4 12 (4.4)
Capecitabine 20 (7.3)
Doxifluridine for 1 yr 110 (40.0)
Relapse 80 (20.2)
Death 37 (9.3)
CEA, carcinoembryonic antigen; FOLFOX-4, oxaloplatin, leucov-
orin, and fluorouracil.
Table 1. Patient characteristics
The genotypes for each single-nucleotide polymorphism were analyzed as categorical variables in three-groups (reference model). p-values cor-
respond to multivariate analysis adjusted for age, differentiation, carcinoembryonic antigen level, and pathologic stage. MAF, minor allele frequency;
HWE, Hardy-Weinberg equilibrium test;CASP, CASPASE.
Table 2. Genotype frequencies and multivariate survival analysis
Genotype
Genotype Disease-free survival Overall survival
Minor allele MAF HWE  p-value p-value p-value
CASP3 rs2705879     G 0.184 0.133 0.156 0.254
CASP6 rs1042891 T 0.613 0.842 0.542 0.168
rs2301717 T 0.429 0.774 0.369 0.785
CASP7 rs2227310 G 0.424 0.208 0.267 0.485
rs11593766 G 0.093 0.121 0.684 0.724
CASP8 rs3769818 T 0.246 0.090 0.423 0.652
rs3834129 Del 0.008 0.874 0.223 0.453
CASP9 rs1052571 C 0.405 0.843 0.687 0.762
rs4645978 G 0.016 0.751 0.354 0.485
CASP10rs13006529 A 0.205 0.271 0.214 0.324
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relation was observed between any given frequency of the genotype or
allele and clinicopathologic parameters, including for T, N, or M stage
patients (data not shown). A multivariate survival analysis including patho-
logic stage, patient age, differentiation, and CEA level demonstrated there
was no association between any genotypes with outcomes for DFS or OS
(Table 2). In haplotype analysis of the CASP6, CASP8and CASP9genes,
none were associated with colorectal cancer prognosis. In terms of clini-
copathologic parameters in a Cox model, patient age, CEA level, and
TNM stage were all significant prognostic factors for DFS and OS (Table
3).
Discussion
The prognostic impact of 10 SNPs of CASPgenes was investigated in
a large population of patients with curatively resected colorectal adeno-
carcinoma. However, no association was observed between the polymor-
phisms in the CASP genes and survival in these patients. Given the
homogenous ethnic background of the patients (Korean), any potential
confounding effect due to ethnicity is likely to be small in the present
study.
Since the CASP pathway plays an important role in balancing cell
growth and death, it is possible that germ line polymorphisms in these
genes may affect an individual’s cancer risk or prognosis. In a previous
study by Yoo et al. [17], significant associations between the CASP7
rs2227310 and CASP9 rs4645981 polymorphisms and prognosis were
found in 411 Korean patients with early stage NSCLC. However, these
same polymorphisms were found to have no prognostic significance in
the survival rate of colorectal cancer patients in the current study. In the
Yoo et al.’s study [17], the CASP9rs4645981 TT genotype was found to
be significantly associated with poor survival outcomes, suggesting that
a lower production genotype for CASP9may have decreased the capacity
for CASP9to mediate the apoptotic activity required to eliminate mutated
or transformed cells, which would thus increase the risk of lung cancer
development and lead to poor survival outcomes in patients with early-
stage NSCLC. Although it remains to be elucidated whether or not the
CASP7 rs2227310C＞G polymorphism itself affects protein character-
istics, interaction sites, or protein solubility or stability, this polymorphism
was associated with poor survival outcomes for patients suffering with
NSCLC [17]. 
Relatively few studies have investigated these polymorphisms and their
relationship to the risks or clinical outcomes of other solid tumors, includ-
ing colorectal cancer, and the results are inconsistent [11,14,15,22-24].
For example Liu et al. [22], reported that 2 caspase-8 SNPs were not as-
sociated with colorectal cancer risk in a study conducted with 373 Chinese
patients and 838 controls. In our previous study that analyzed 15 SNPs of
apoptosis-related genes and their impact on the response to chemotherapy
and survival of colorectal cancer patients, no significant association be-
tween patient response or survival and the polymorphisms of the CASP3
or CASP6to CASP10genes was observed [23]. 
Given that validation of genotype-phenotype association studies re-
quires replication using an independent data set, additional studies are re-
quired to confirm the associations between CASPgene polymorphisms
and survival outcomes in the cancer patients observed in our previous
study. 
Table 3. Multivariate survival analysis
Characteristics
Disease-free survival Overall survival
HR 95% CI p-value HR 95% CI p-value
Age (yr) 0.068 0.012
≤63 11
＞63 1.55 0.97-2.48 2.58 1.25-5.47
Differentiation 0.501 0.074
Well 11
Moderate 1.49 0.73-3.02 0.270 0.90 0.34-2.39 0.836
Poor 1.83 0.48-6.92 0.38 3.23 0.82-12.82 0.095
Stage ＜0.001 ＜0.001
I1 1
II 2.09 0.57-7.60 0.264 1.38 0.25-7.82 0.713
III 10.88 3.30-35.78 ＜0.001 7.85 1.76-35.09 0.007
IV 38.15 10.43-139.53 ＜0.001 23.30 4.45-122.04 ＜0.001
CEA level 0.005 0.192
Normal 11
Elevated 1.98 1.23-3.20 1.59 0.79-3.19
p-values correspond to multivariate Cox model adjusted for age, differentiation, CEA level, and pathologic stage. HR, hazard ratio; CI, confidence
interval; CEA, carcinoembryonic antigen.
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C onclusion
None of the 10 CASPgene SNPs investigated in this study was found
to be an independent prognostic marker for Korean patients with cura-
tively resected colorectal cancer. However, since genetic polymorphisms
often vary between ethnic groups, further studies clarifying the association
between these polymorphisms and the prognosis of colorectal cancer in
diverse ethnic populations are warranted.
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